Key terms
About PALI
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PALI news
Apr 17
11:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)
Apr 16
8:33am ET
Palisade Bio demonstrates bioactivation of PALI-2108
Apr 05
7:50pm ET
Palisade Bio Inc trading halted, news pending
Apr 03
5:32pm ET
Palisade Bio announces 1-for-15 reverse stock split
Mar 29
6:58pm ET
Palisade Bio files to sell 3.63M shares of common stock for holders
Mar 28
10:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)
Mar 28
2:00am ET
Palisade Bio, Inc.’s Success on the Line: The Critical Role of Retaining Top Talent Without Safeguards
Mar 27
8:07am ET
Palisade Bio reports FY23 EPS ($1.80) vs ($16.53) last year
Feb 13
4:52pm ET
Palisade Bio’s Corporate Shake-Up Sparks Investor Interest
Feb 08
8:16am ET
Palisade Bio announces formation of clinical advisory board
Jan 31
7:40am ET
Analysts’ Top Healthcare Picks: Vaxart (VXRT), Palisade Bio (PALI)
Jan 30
9:27am ET
Palisade Bio exercises previously issued warrants fo $2.5M
PALI Financials
Key terms
Ad Feedback
PALI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PALI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
